Last edition
News about "Antibody Drug Conjugate (ADC) "
Orum Therapeutics Appoints Dr Chad May as Chief Scientific Officer
Orum Therapeutics has appointed Dr Chad May, PhD, as Chief Scientific Officer (CSO), who brings over two decades of oncology and immunology research experience to advance the company’s degrader-antibody conjugate platform and pipeline of next-generation therapies.
Antibody Drug Conjugate (ADC) | 05/01/2026 | By News Bureau
Daiichi Sankyo has dosed the first patient in a phase 1 clinical trial of DS3610, its investigational STING agonist Antibody Drug Conjugate (ADC), marking a key step in advancing novel immunotherapy approaches for patients with advanced solid tumours.
Antibody Drug Conjugate (ADC) | 12/11/2025 | By Dineshwori | 452
Daiichi Sankyo Files sNDA in Japan for ENHERTU Plus Pertuzumab in HER2-Positive Breast Cancer
Daiichi Sankyo has filed a supplemental NDA in Japan for ENHERTU plus Pertuzumab in HER2-positive breast cancer. If approved, this therapy could enter the first-line metastatic setting and has the potential to become a new standard of care.
<br />
Antibody Drug Conjugate (ADC) | 08/10/2025 | By Dineshwori | 480
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy